Literature DB >> 29063238

Metabolic advantages and vulnerabilities in brain metastases.

Alexandra K Ciminera1,2, Rahul Jandial3, John Termini4.   

Abstract

Metabolic adaptations permit tumor cells to metastasize to and thrive in the brain. Brain metastases continue to present clinical challenges due to rising incidence and resistance to current treatments. Therefore, elucidating altered metabolic pathways in brain metastases may provide new therapeutic targets for the treatment of aggressive disease. Due to the high demand for glucose in the brain, increased glycolytic activity is favored for energy production. Primary tumors that undergo Warburg-like metabolic reprogramming become suited to growth in the brain microenvironment. Indeed, elevated metabolism is a predictor of metastasis in many cancer subtypes. Specifically, metabolic alterations are seen in primary tumors that are associated with the formation of brain metastases, namely breast cancer, lung cancer, and melanoma. Because of this selective pressure, inhibitors of key metabolic factors may reduce tumor cell viability, thus exploiting metabolic pathways for cancer therapeutics. This review summarizes the metabolic advantages and vulnerabilities of brain metastases.

Entities:  

Keywords:  Brain metastases; Cancer metabolism; Metabolic adaptation

Mesh:

Year:  2017        PMID: 29063238      PMCID: PMC5712254          DOI: 10.1007/s10585-017-9864-8

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  77 in total

Review 1.  Modern methods for delivery of drugs across the blood-brain barrier.

Authors:  Yan Chen; Lihong Liu
Journal:  Adv Drug Deliv Rev       Date:  2011-11-28       Impact factor: 15.470

2.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.

Authors:  Sébastien Bonnet; Stephen L Archer; Joan Allalunis-Turner; Alois Haromy; Christian Beaulieu; Richard Thompson; Christopher T Lee; Gary D Lopaschuk; Lakshmi Puttagunta; Sandra Bonnet; Gwyneth Harry; Kyoko Hashimoto; Christopher J Porter; Miguel A Andrade; Bernard Thebaud; Evangelos D Michelakis
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

3.  Epidemiology of brain metastases.

Authors:  Lakshmi Nayak; Eudocia Quant Lee; Patrick Y Wen
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

4.  Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.

Authors:  Adam Kinnaird; Peter Dromparis; Bruno Saleme; Vikram Gurtu; Kristalee Watson; Roxane Paulin; Sotirios Zervopoulos; Trevor Stenson; Gopinath Sutendra; Desmond B Pink; Katia Carmine-Simmen; Ronald Moore; John D Lewis; Evangelos D Michelakis
Journal:  Eur Urol       Date:  2016-02-18       Impact factor: 20.096

5.  MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4.

Authors:  Candice Sun Hong; Nicholas A Graham; Wen Gu; Carolina Espindola Camacho; Vei Mah; Erin L Maresh; Mohammed Alavi; Lora Bagryanova; Pascal A L Krotee; Brian K Gardner; Iman Saramipoor Behbahan; Steve Horvath; David Chia; Ingo K Mellinghoff; Sara A Hurvitz; Steven M Dubinett; Susan E Critchlow; Siavash K Kurdistani; Lee Goodglick; Daniel Braas; Thomas G Graeber; Heather R Christofk
Journal:  Cell Rep       Date:  2016-02-11       Impact factor: 9.423

6.  Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases.

Authors:  A Ali; J R Goffin; A Arnold; P M Ellis
Journal:  Curr Oncol       Date:  2013-08       Impact factor: 3.677

7.  Glucose metabolism in NSCLC is histology-specific and diverges the prognostic potential of 18FDG-PET for adenocarcinoma and squamous cell carcinoma.

Authors:  Olga C J Schuurbiers; Tineke W H Meijer; Johannes H A M Kaanders; Monika G Looijen-Salamon; Lioe-Fee de Geus-Oei; Miep A van der Drift; Erik H F M van der Heijden; Wim J Oyen; Eric P Visser; Paul N Span; Johan Bussink
Journal:  J Thorac Oncol       Date:  2014-10       Impact factor: 15.609

Review 8.  Sugar for the brain: the role of glucose in physiological and pathological brain function.

Authors:  Philipp Mergenthaler; Ute Lindauer; Gerald A Dienel; Andreas Meisel
Journal:  Trends Neurosci       Date:  2013-08-20       Impact factor: 13.837

9.  Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.

Authors:  Harri Sihto; Johan Lundin; Mikael Lundin; Tiina Lehtimäki; Ari Ristimäki; Kaija Holli; Liisa Sailas; Vesa Kataja; Taina Turpeenniemi-Hujanen; Jorma Isola; Päivi Heikkilä; Heikki Joensuu
Journal:  Breast Cancer Res       Date:  2011-09-13       Impact factor: 6.466

10.  Early Diagnosis of Brain Metastases Using a Biofluids-Metabolomics Approach in Mice.

Authors:  James R Larkin; Alex M Dickens; Timothy D W Claridge; Claire Bristow; Kleopatra Andreou; Daniel C Anthony; Nicola R Sibson
Journal:  Theranostics       Date:  2016-09-12       Impact factor: 11.556

View more
  15 in total

1.  Curing brain metastases.

Authors:  Rahul Jandial
Journal:  Clin Exp Metastasis       Date:  2017-10       Impact factor: 5.150

2.  Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness.

Authors:  Pravat Kumar Parida; Mauricio Marquez-Palencia; Vidhya Nair; Akash K Kaushik; Kangsan Kim; Jessica Sudderth; Eduardo Quesada-Diaz; Ambar Cajigas; Vamsidhara Vemireddy; Paula I Gonzalez-Ericsson; Melinda E Sanders; Bret C Mobley; Kenneth Huffman; Sunati Sahoo; Prasanna Alluri; Cheryl Lewis; Yan Peng; Robert M Bachoo; Carlos L Arteaga; Ariella B Hanker; Ralph J DeBerardinis; Srinivas Malladi
Journal:  Cell Metab       Date:  2022-01-04       Impact factor: 31.373

Review 3.  Novel Systemic Treatments for Brain Metastases From Lung Cancer.

Authors:  Bicky Thapa; Adam Lauko; Kunal Desai; Vyshak Alva Venur; Manmeet S Ahluwalia
Journal:  Curr Treat Options Neurol       Date:  2018-09-27       Impact factor: 3.598

4.  Serum irisin associates with breast cancer to spinal metastasis.

Authors:  Zheng-Ping Zhang; Xue-Fang Zhang; Hui Li; Tuan-Jiang Liu; Qin-Peng Zhao; Lin-Hong Huang; Zi-Jun Cao; Li-Min He; Ding-Jun Hao
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.817

5.  FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis.

Authors:  Alex Cordero; Deepak Kanojia; Jason Miska; Wojciech K Panek; Annie Xiao; Yu Han; Nicolas Bonamici; Weidong Zhou; Ting Xiao; Meijing Wu; Atique U Ahmed; Maciej S Lesniak
Journal:  Oncogene       Date:  2019-07-19       Impact factor: 9.867

Review 6.  The Metabolic Mechanisms of Breast Cancer Metastasis.

Authors:  Lingling Wang; Shizhen Zhang; Xiaochen Wang
Journal:  Front Oncol       Date:  2021-01-07       Impact factor: 6.244

Review 7.  Autophagy-mediated tumor cell survival and progression of breast cancer metastasis to the brain.

Authors:  Aparna Maiti; Nitai C Hait
Journal:  J Cancer       Date:  2021-01-01       Impact factor: 4.207

8.  Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models.

Authors:  Rahul Jandial; Josh Neman; Punnajit P Lim; Daniel Tamae; Claudia M Kowolik; Gerald E Wuenschell; Sarah C Shuck; Alexandra K Ciminera; Luis R De Jesus; Ching Ouyang; Mike Y Chen; John Termini
Journal:  Int J Mol Sci       Date:  2018-01-30       Impact factor: 5.923

Review 9.  Systemic Therapy of Metastatic Melanoma: On the Road to Cure.

Authors:  Julian Steininger; Frank Friedrich Gellrich; Alexander Schulz; Dana Westphal; Stefan Beissert; Friedegund Meier
Journal:  Cancers (Basel)       Date:  2021-03-20       Impact factor: 6.639

10.  Preoperative stereotactic radiosurgery for brain metastases: the STEP study protocol for a multicentre, prospective, phase-II trial.

Authors:  Angeline Ginzac; Guillaume Dupic; Lucie Brun; Ioana Molnar; Mélanie Casile; Xavier Durando; Pierre Verrelle; Jean-Jacques Lemaire; Toufic Khalil; Julian Biau
Journal:  BMC Cancer       Date:  2021-07-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.